PD-0325901
Clinical Trials Overview
3 trials found
About PD-0325901
PD-0325901 is a potent, selective MEK inhibitor that targets the mitogen-activated protein kinase (MAPK) signaling pathway in colorectal cancer. This compound has been evaluated specifically in combination therapies for KRAS-mutant colorectal cancers, where aberrant MEK signaling drives tumor growth. It represents a targeted approach to block downstream effects of KRAS mutations, which occur in approximately 40-50% of colorectal cancer patients and confer resistance to EGFR-targeted therapies.
Category
Other Medications
Brand Name
Not yet branded
Mechanism
PD-0325901 works by selectively inhibiting MEK1 and MEK2, which are critical kinases in the RAS/RAF/MEK/ERK signaling cascade. By blocking MEK activity, the drug prevents phosphorylation and activation of ERK, thereby disrupting cellular proliferation, survival signals, and tumor growth in KRAS-mutant cancer cells.
3
Total Trials
0
Recruiting
0
Active
3
Completed
196
Total Enrollment
3
Countries
NCT02510001
Phase 1
Completed
82 patients
This trial is designed to try two new cancer drugs together for the first time. The investigators think that they might be effective in some types of bowel cancer. The first part of the trial will see what doses of the two drugs can safely be given t...
United Kingdom
NCT02039336
Phase 1
Completed
35 patients
This is a phase I/II multi-center open-label proof of concept study, consisting of two parts. Part A of this study is designed to identify the recommended phase 2 dose (RP2D) of the combination regimen of dacomitinib plus PD-0325901 in patients with ...
Netherlands
NCT00147550
Phase 1
Completed
79 patients
Medications:
PD-0325901
MEK is a critical member of the MAPK pathway involved in growth and survival of cancer cells. PD-325901 is a new drug designed to block this pathway and kill cancer cells. The purpose of this study is to study the effectiveness of PD-325901 in patien...
United States